Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BSL_EP028 is a combination product comprised of multiple plant extracts, marketed under the brand name Dibifree. It is investigated primarily for its potential in improving joint mobility, physical performance, and vitality, as well as for regulating blood sugar and hemoglobin A1c in patients with type 2 diabetes. The product contains the following ingredients: bitter melon (Momordica charantia) fruit extract, celery (Apium graveolens) seed extract, baker's yeast (Saccharomyces cerevisiae) cell wall extract, acerola (Malpighia emarginata) fruit extract, grape (Vitis vinifera) seed extract, green tea leaf extract, and hydrolyzed soy protein powder. The exact mechanism of action is not fully characterized, and its therapeutic activity is attributed to the combined effects of these bioactive plant-derived compounds, which are hypothesized to possess antioxidant, anti-inflammatory, and metabolic-modulating properties[3][5][1][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BSL_EP028.